These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 34857666)

  • 1. Patient perception and treatment convenience of dabigatran versus vitamin K antagonist when used for stroke prophylaxis in atrial fibrillation: Real-world Evaluation of Long-term Anticoagulant Treatment Experience (RE-LATE) study.
    Lee YS; Oh YS; Choi EK; Chern AKC; Jiampo P; Chutinet A; Hanafy DA; Trivedi P; Zhai D
    Open Heart; 2021 Dec; 8(2):. PubMed ID: 34857666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world evaluation of perception, convenience and anticoagulant treatment satisfaction of patients with atrial fibrillation switched from long-term vitamin K antagonist treatment to dabigatran.
    Choi EK; Lee YS; Chern AKC; Jiampo P; Chutinet A; Hanafy DA; Trivedi P; Zhai D; Oh YS
    Open Heart; 2020 Nov; 7(2):. PubMed ID: 33184127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study.
    Vinereanu D; Napalkov D; Bergler-Klein J; Benczur B; Ciernik M; Gotcheva N; Medvedchikov A; Põder P; Simić D; Skride A; Tang W; Trusz-Gluza M; Vesely J
    J Thromb Thrombolysis; 2021 Nov; 52(4):1195-1206. PubMed ID: 33929686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study).
    Vinereanu D; Napalkov D; Bergler-Klein J; Benczur B; Ciernik M; Gotcheva N; Medvedchikov A; Põder P; Simic D; Skride A; Tang W; Trusz-Gluza M; Vesely J; Vishnepolsky T; Vrabec M
    Open Heart; 2020; 7(1):e001202. PubMed ID: 32257246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient satisfaction with dabigatrean and warfarin for stroke prevention in atrial fibrillation: Taiwan PASSION study.
    Lee CW; Liu ME; Lee TM; Chang RY; Huang CY; Hu YF; Yeh HI
    J Chin Med Assoc; 2021 Apr; 84(4):375-382. PubMed ID: 33784265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
    Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment Satisfaction and Convenience for Patients With Atrial Fibrillation on Edoxaban or Vitamin K Antagonists After Transcatheter Aortic Valve Replacement: A Post Hoc Analysis from the ENVISAGE-TAVI AF Trial.
    Hengstenberg C; Van Mieghem NM; Wang R; Ye X; Shi L; Guo S; Chen C; Jin J; Ye X; Dangas G; Unverdorben M
    Am J Cardiol; 2023 Dec; 209():212-219. PubMed ID: 37848174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
    Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
    Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
    Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
    Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabigatran and vitamin K antagonists' use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records.
    Vlacho B; Giner-Soriano M; Zabaleta-Del-Olmo E; Roso-Llorach A; García-Sangenís A; Morros-Pedrós R
    Eur J Clin Pharmacol; 2017 Oct; 73(10):1323-1330. PubMed ID: 28725983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies.
    Liu X; Xu ZX; Yu P; Yuan P; Zhu WG
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):569-578. PubMed ID: 32297024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.
    Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S
    BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients' perceptions with dabigatran in patients with atrial fibrillation previously treated with vitamin K antagonists.
    Barrios V; Escobar C; Gómez-Doblas JJ; Fernández-Dueñas J; Garrido RR; Rodríguez JP; Sánchez JU; Arellano-Rodrigo E; Donado E;
    J Comp Eff Res; 2020 Jun; 9(9):615-625. PubMed ID: 32469278
    [No Abstract]   [Full Text] [Related]  

  • 19. Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry.
    Huisman MV; Teutsch C; Lu S; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Lohmann R; Gurusamy VK; Bartels DB; Lip GYH;
    Clin Res Cardiol; 2022 May; 111(5):548-559. PubMed ID: 35294623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists.
    Sørensen R; Jamie Nielsen B; Langtved Pallisgaard J; Ji-Young Lee C; Torp-Pedersen C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jul; 3(3):151-156. PubMed ID: 28158553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.